Development of therapeutic and prophylactic vaccine against tuberculosis using monkey and transgenic mice models

Human Vaccines

Volumn 7, Issue SUPPL., 2011, Pages 108-114

  Kita, Yoko ^a   Okada, Masaji ^a   Nakajima, Toshihiro ^b   Kanamaru, Noriko ^a   Hashimoto, Satomi ^a   Nagasawa, Tetsuji ^b   Kaneda, Yasufumi ^c   Yoshida, Shigeto ^d   Nishida, Yasuko ^a   Nakatani, Hitoshi ^a   Takao, Kyoko ^a   Kishigami, Chie ^a   Nishimatsu, Shiho ^a   Sekine, Yuki ^a   Takamori, Yasushi ^c   McMurray, David N ^f   De La Cruz, E C ^g   Tan, E V ^g   Abalos, R M ^e,g   Burgos, J A ^g   Saunderson, Paul ^g   Sakatani, Mitsunori ^a   more..

^a NATIONAL HOSPITAL ORGANIZATION KINKI CHUO CHEST MEDICAL CENTER   (Japan)

^b GenomIdea Inc   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d Jichi MedSch ^*  (Japan)

^e Cell Therapy Research Division   (Japan)

^f TEXAS A AND M UNIVERSITY   (United States)

^g Leonard Wood Memorial Center for Leprosy Research Philippines   (Philippines)

Author keywords

15 KDa granulyin; Granulysin transgenic mouse; HVJ envelope HSP65DNA + IL 12DNA; Monkey; Mycobacterium tuberculosis; Patients with tuberculosis; Prime boost method; Prophylactic efficacy; SCID PBL hu; Vaccine

Indexed keywords

BCG VACCINE; DNA VACCINE; GRANULYSIN; HEAT SHOCK PROTEIN 65; INTERLEUKIN 12;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BCG VACCINATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; HAPLORHINI; INFECTION PREVENTION; INFECTION RESISTANCE; MOUSE; NONHUMAN; REVIEW; SURVIVAL TIME; TRANSGENIC MOUSE; TUBERCULOSIS; WEIGHT GAIN;

ANIMALS; BACTERIAL PROTEINS; CELL PROLIFERATION; CHAPERONIN 60; DISEASE MODELS, ANIMAL; IMMUNIZATION, SECONDARY; INTERLEUKIN-12; LEUKOCYTES, MONONUCLEAR; MACACA FASCICULARIS; MICE; MICE, SCID; MICE, TRANSGENIC; MYCOBACTERIUM TUBERCULOSIS; PRIMATE DISEASES; RECOMBINANT PROTEINS; RODENT DISEASES; TUBERCULOSIS VACCINES; VACCINATION;

EID: 79955092506     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.0.14571     Document Type: Review

References (17)

1. Walsh GP, Tan EV, dela Cruz EC, Abalos RM, Villahermosa LG, Young LJ, et al. The Philippine cynomolgus monkey provides a new nonhuman primate model of tuberculosis that resembles human disease. Nat Med 1996; 2:430-6. (Pubitemid 26191915)
2. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-5. (Pubitemid 40341439)
3. Okada M, Kita Y, Nakajima T, Kanamaru N, Hashimoto S, Nagasawa T, et al. Evaluation of a novel vaccine (HVJ-liposome/HSP65 DNA + IL-12 DNA) against tuberculosis using the cynomologus monkey model of TB. Vaccine 2007; 25:2990-3. (Pubitemid 46509463)
4. Tanaka F, Abe M, Akiyoshi T, Nomura T, Sugimachi K, Kishimoto T, et al. The anti-human tumor effect and generation of human cytotoxic T cells in SCID mice given human peripheral blood lymphocytes by the in vivo transfer of the Interleukin-6 gene using adenovirus vector. Cancer Res 1997; 57:1335-43. (Pubitemid 27152560)
5. Oada M, Okuno Y, Hashimoto S, Kita Y, Kanamaru N, Nishida Y, et al. Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/ hu mouse models. Vaccine 2007; 25:3038-40. (Pubitemid 46509464)
6. Pena SV, Hanson DA, Carr BA, Goralski TJ, Krensky M. Processing, subcellular localization and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J Immunol 1997; 158:2680-8. (Pubitemid 127470525)
7. Stenger S, Hanson DA, Teitelbaum R, Dewan P, Niazi KR, Froelich CJ, et al. An antimicrobial activity of cytolytic T cells mediatd by granulysin. Science 1998; 282:121-5. (Pubitemid 28471143)
8. Huang LP, Lyu SC, Clayberger C, Krensky AM. Granulysin-mediated tumor rejection in transgenic mice. J Immunol 2007; 178:77-84. (Pubitemid 46033589)
9. Yoshida S, Tanaka T, Kita Y, Kuwayama S, Kanamaru N, Muraki Y, et al. DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation. Vaccine 2006; 24:1191-204. (Pubitemid 43202265)
10. Kita Y, Tanaka T, Yoshida S, Ohara N, Kaneda Y, Kuwayama S, et al. Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model. Vaccine 2005; 23:2132-5. (Pubitemid 40341439)
11. Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T. IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 1988; 141:1543-9.
12. Okada M, Yoshimura N, Kaieda T, Yamamura Y, Kishimoto T. Establishment and characterization of human T hybrid cells secreting immunoregulatory molecules. Proc Natl Acad Sci USA 1981; 78:7717-21. (Pubitemid 12186633)
13. Okada M, Sakaguchi N, Yoshimura N, Hara H, Shimizu K, Yoshida N, et al. B cell growth factor and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med 1983; 157:583-90. (Pubitemid 13145061)
14. McShane H, Pathan AA, Sander CR, Keating SM, Gilbert SC, Huygen K, et al. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nature Med 2008; 10:1240-4. (Pubitemid 39540442)
15. Fletcher HA, Pathan AA, Berthoud TK, Dunachie SJ, Whela KT, Alder NC, et al. Boosting BCG vaccination with MVA85A domn-regulates the immunoregulatory cytokine TGFβ1. Vaccine 2008; 26:5264-75.
16. Okada M, Kita Y. Tuberculosis vaccine development: The development of novel (preclinical) DNA vaccine. Human Vaccine 2010; 6:297-308.
17. Kaufmann SHE. New vaccine for tuberculosis. The Lancet 2010; 375:85-94.